[Molnupiravir reduces symptoms duration but does not decrease hospitalizations or deaths in vaccinated adults with Covid-19.]

Q3 Medicine Recenti progressi in medicina Pub Date : 2024-09-01 DOI:10.1701/4334.43180

Peter K Kurotschka, Mark H Ebell, Alice Serafini

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[在接种了Covid-19疫苗的成年人中，莫诺比拉韦能缩短症状持续时间，但不能减少住院或死亡人数]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Recenti progressi in medicina Medicine-Medicine (all)

CiteScore

0.90

自引率

0.00%

发文量

143

期刊介绍： Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.

期刊最新文献

[Anticoagulant therapy in venous thromboembolism and bleeding risk: focus on the use of predictive scores.] [Human vs. ChatGPT. Is it possible obtain comparable results in the analysis of a scientific systematic review?] [Is there a correlation between increasing hospital falls and Covid-19 infection? Retrospective study on the entire hospital population.] [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.] [Molnupiravir reduces symptoms duration but does not decrease hospitalizations or deaths in vaccinated adults with Covid-19.]